Venkateshwar Chinthalapally
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 9 | 2022 | 121 | 1.920 |
Why?
|
| Adenocarcinoma | 5 | 2022 | 300 | 1.190 |
Why?
|
| Adenoma | 4 | 2021 | 61 | 0.880 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 141 | 0.850 |
Why?
|
| Anticarcinogenic Agents | 4 | 2019 | 16 | 0.810 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2021 | 120 | 0.760 |
Why?
|
| Naproxen | 3 | 2021 | 15 | 0.740 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2021 | 61 | 0.670 |
Why?
|
| Azoxymethane | 7 | 2021 | 20 | 0.650 |
Why?
|
| Aspirin | 4 | 2019 | 125 | 0.650 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 681 | 0.640 |
Why?
|
| Genomic Instability | 4 | 2022 | 34 | 0.610 |
Why?
|
| Apoptosis | 7 | 2021 | 777 | 0.580 |
Why?
|
| Animals | 24 | 2021 | 10583 | 0.540 |
Why?
|
| Signal Transduction | 6 | 2018 | 1455 | 0.530 |
Why?
|
| Mutation | 4 | 2021 | 864 | 0.530 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 64 | 0.520 |
Why?
|
| N-Acetylglucosaminyltransferases | 2 | 2016 | 16 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 163 | 0.500 |
Why?
|
| Lipoxygenase | 2 | 2014 | 3 | 0.480 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2014 | 24 | 0.470 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 167 | 0.430 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 548 | 0.420 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 357 | 0.420 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 104 | 0.410 |
Why?
|
| Isothiocyanates | 1 | 2013 | 11 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2015 | 164 | 0.400 |
Why?
|
| Carcinoma in Situ | 2 | 2014 | 46 | 0.400 |
Why?
|
| Mice | 14 | 2021 | 4735 | 0.390 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 115 | 0.390 |
Why?
|
| Diet | 2 | 2013 | 232 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 141 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 137 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 146 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 78 | 0.350 |
Why?
|
| Sea Cucumbers | 2 | 2015 | 2 | 0.350 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2018 | 19 | 0.340 |
Why?
|
| Alendronate | 1 | 2019 | 6 | 0.320 |
Why?
|
| Neoplasms | 3 | 2016 | 857 | 0.320 |
Why?
|
| Metformin | 1 | 2019 | 36 | 0.310 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 58 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 465 | 0.310 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 509 | 0.290 |
Why?
|
| Receptors, Enterotoxin | 1 | 2018 | 5 | 0.290 |
Why?
|
| Paracrine Communication | 1 | 2018 | 17 | 0.290 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 19 | 0.290 |
Why?
|
| Cyclic GMP | 1 | 2018 | 29 | 0.290 |
Why?
|
| Hormones | 1 | 2018 | 44 | 0.290 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2013 | 10 | 0.280 |
Why?
|
| Humans | 20 | 2022 | 28585 | 0.280 |
Why?
|
| Rats | 6 | 2021 | 1587 | 0.280 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 472 | 0.270 |
Why?
|
| Rats, Inbred F344 | 5 | 2021 | 174 | 0.270 |
Why?
|
| Genes, APC | 3 | 2015 | 14 | 0.270 |
Why?
|
| Chromosomal Instability | 2 | 2015 | 21 | 0.270 |
Why?
|
| Mitosis | 3 | 2015 | 115 | 0.270 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 7 | 0.260 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.260 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 187 | 0.260 |
Why?
|
| Chromosome Segregation | 2 | 2009 | 57 | 0.250 |
Why?
|
| Carcinogens | 4 | 2021 | 39 | 0.250 |
Why?
|
| Curcumin | 1 | 2007 | 69 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 337 | 0.240 |
Why?
|
| Mucin-1 | 1 | 2016 | 36 | 0.240 |
Why?
|
| Muscles | 1 | 2015 | 73 | 0.230 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2015 | 133 | 0.230 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 82 | 0.230 |
Why?
|
| Eflornithine | 1 | 2014 | 3 | 0.220 |
Why?
|
| Ornithine Decarboxylase | 1 | 2014 | 9 | 0.220 |
Why?
|
| Uroplakin II | 1 | 2014 | 5 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2019 | 817 | 0.220 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2014 | 5 | 0.220 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 236 | 0.220 |
Why?
|
| Pyrroles | 1 | 2014 | 36 | 0.210 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2013 | 8 | 0.210 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 5 | 0.210 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 16 | 0.210 |
Why?
|
| Escin | 1 | 2013 | 1 | 0.210 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 8 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 133 | 0.210 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 12 | 0.210 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 25 | 0.210 |
Why?
|
| Male | 11 | 2021 | 13772 | 0.200 |
Why?
|
| Antimitotic Agents | 1 | 2012 | 5 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 611 | 0.200 |
Why?
|
| Chemoprevention | 3 | 2018 | 32 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 1341 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 66 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 54 | 0.190 |
Why?
|
| Plant Extracts | 2 | 2018 | 62 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 190 | 0.190 |
Why?
|
| Biological Products | 1 | 2012 | 66 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 328 | 0.180 |
Why?
|
| Female | 10 | 2021 | 15472 | 0.170 |
Why?
|
| Blotting, Western | 4 | 2015 | 515 | 0.170 |
Why?
|
| RNA, Messenger | 4 | 2015 | 667 | 0.160 |
Why?
|
| Intestinal Neoplasms | 2 | 2015 | 15 | 0.150 |
Why?
|
| Microtubules | 1 | 2009 | 90 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2013 | 81 | 0.140 |
Why?
|
| Momordica charantia | 1 | 2018 | 1 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 1602 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2008 | 128 | 0.140 |
Why?
|
| Disease Progression | 3 | 2014 | 475 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 275 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 208 | 0.120 |
Why?
|
| Acetates | 1 | 2006 | 45 | 0.120 |
Why?
|
| Dinoprostone | 2 | 2021 | 42 | 0.120 |
Why?
|
| Indoles | 1 | 2006 | 110 | 0.120 |
Why?
|
| Complex Mixtures | 1 | 2015 | 12 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 24 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2005 | 151 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 3 | 2013 | 68 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 314 | 0.100 |
Why?
|
| Aberrant Crypt Foci | 1 | 2013 | 2 | 0.100 |
Why?
|
| alpha-Linolenic Acid | 1 | 2013 | 5 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 231 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 36 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2022 | 82 | 0.090 |
Why?
|
| Omeprazole | 1 | 2021 | 9 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 410 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 27 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 29 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 104 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1494 | 0.090 |
Why?
|
| Transcriptome | 1 | 2022 | 214 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 135 | 0.080 |
Why?
|
| Alleles | 1 | 2021 | 354 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 148 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 40 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2019 | 104 | 0.080 |
Why?
|
| beta Catenin | 2 | 2012 | 66 | 0.080 |
Why?
|
| Lung | 1 | 2022 | 380 | 0.080 |
Why?
|
| Rats, Wistar | 1 | 2019 | 153 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2019 | 190 | 0.080 |
Why?
|
| Celecoxib | 1 | 2018 | 10 | 0.070 |
Why?
|
| Hemostasis | 1 | 2018 | 48 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 74 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 76 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 25 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 86 | 0.060 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 50 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2016 | 63 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2007 | 244 | 0.060 |
Why?
|
| Polyamines | 1 | 2015 | 13 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 251 | 0.060 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2015 | 2 | 0.060 |
Why?
|
| Glypicans | 1 | 2015 | 3 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 288 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 18 | 0.060 |
Why?
|
| Transfection | 1 | 2016 | 319 | 0.060 |
Why?
|
| Haploinsufficiency | 1 | 2015 | 8 | 0.060 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 31 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 186 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2015 | 16 | 0.060 |
Why?
|
| Sirolimus | 1 | 2015 | 76 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 68 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2015 | 119 | 0.060 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2014 | 2 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2015 | 48 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 45 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 414 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2015 | 208 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 468 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 128 | 0.050 |
Why?
|
| DNA Damage | 1 | 2015 | 151 | 0.050 |
Why?
|
| Retinoid X Receptors | 1 | 2013 | 24 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2013 | 5 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 10 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 14 | 0.050 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 33 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 105 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 90 | 0.050 |
Why?
|
| Tobacco | 1 | 2013 | 87 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 19 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 344 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2012 | 38 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2013 | 291 | 0.050 |
Why?
|
| Integrases | 1 | 2012 | 39 | 0.050 |
Why?
|
| Cell Movement | 1 | 2014 | 373 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2015 | 1009 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 68 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 250 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 834 | 0.040 |
Why?
|
| Inflammation | 1 | 2015 | 642 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2009 | 2 | 0.040 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 4 | 0.040 |
Why?
|
| Mad2 Proteins | 1 | 2009 | 10 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 62 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 52 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 18 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 72 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 29 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2008 | 58 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 22 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2009 | 119 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 123 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 249 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 10 | 0.030 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 58 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 2005 | 17 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2015 | 57 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 80 | 0.030 |
Why?
|
| Aged | 1 | 2013 | 5525 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 166 | 0.030 |
Why?
|
| Gene Expression | 1 | 2005 | 417 | 0.030 |
Why?
|
| Corn Oil | 1 | 2013 | 2 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 9 | 0.020 |
Why?
|
| Plant Oils | 1 | 2013 | 10 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 448 | 0.020 |
Why?
|
| Middle Aged | 1 | 2013 | 7310 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 197 | 0.020 |
Why?
|
| Adult | 1 | 2013 | 7922 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 485 | 0.020 |
Why?
|